Part 9/Chapter 52/18-min read

Venous Thromboembolism Prevention, Diagnosis, and Acute Lower-Extremity Deep Vein Thrombosis

Prevention, diagnosis, and treatment of acute lower-extremity deep vein thrombosis: pathophysiology and epidemiology, risk assessment and prophylaxis, diagnosis, anticoagulation, endovascular and surgical thrombus removal, cancer-associated disease, and duration of therapy.

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Version 1 · Last published ·10 sections · 54 references

Revision history

Listen to this chapter24 min · AI audio edition · two hostsAI narration

Choose a chapter overview or a specialist discussion. Each recording follows this published edition.

General medical education, not patient-specific advice.

Choose an audio edition

Definition and presentation

Deep vein is thrombus formation in the deep veins, usually of the lower limb; it is one manifestation of venous thromboembolism . A proximal deep-vein thrombus can embolize to the pulmonary arteries to cause pulmonary , the other manifestation of the venous thromboembolism spectrum. Proximal disease carries the greatest embolic risk.

Many deep vein thromboses are clinically silent and signs are non-specific, necessitating clinical probability scoring and objective testing . Typical clinical features include: - Unilateral limb swelling (iliofemoral disease typically causes whole-limb swelling) - Pain or tenderness, often localized to the calf - Warmth - Erythema

Pathophysiology

Venous thrombosis arises from Virchow's triad: stasis, endothelial injury, and hypercoagulability . Thrombus typically forms in the valve pockets of the calf veins, where stasis and local hypoxia activate coagulation. Most calf thrombi resolve or stay confined; a minority propagate proximally into the popliteal, femoral, and iliac veins. This proximal extension drives pulmonary embolism and post-thrombotic syndrome .

Iliofemoral thrombosis carries the greatest post-thrombotic burden. Persistent outflow obstruction and valvular reflux produce ambulatory venous hypertension, which underlies chronic limb swelling, pain, and ulceration . May-Thurner anatomy (compression of the left common iliac vein by the overlying right common iliac artery) predisposes to left-sided iliofemoral deep vein thrombosis, particularly in younger women.

Phlegmasia cerulea dolens is the extreme of the clinical spectrum: near-total venous outflow occlusion raises compartment pressures, compromises arterial inflow, and threatens limb viability .

Epidemiology and risk factors

The Worcester community study reported a venous thromboembolism incidence of 104 per 100,000 population per year and an attack rate of 128 per 100,000, based on events in 1999. These are historical regional estimates, not contemporary global rates . Incidence rises steeply with age, from under 1 per 1000 per year in young adults to nearly 1 per 100 per year after age 80 .

Further reading: Heit’s review provides an overview of epidemiology and risk factors .

High-risk and sex-specific risk factors include : - Pregnancy and the puerperium (risk is particularly high in the postpartum period) - Estrogen-containing contraception and hormone therapy - Active cancer - Recent surgery or trauma - Immobility - Prior venous thromboembolism - Inherited thrombophilia - Advancing age

Hospitalized, post-operative, immobile, and oncologic patients carry the highest short-term risk, and many at-risk inpatients receive no guideline-recommended prophylaxis .

Risk assessment and prophylaxis

Assess venous thromboembolism and bleeding risk together, using the clinical setting and planned procedure rather than a score alone. In the CHEST general and abdominal-pelvic surgical framework, Caprini ≥5 identifies a high-risk category for which low-molecular-weight heparin or low-dose unfractionated heparin is recommended when major bleeding risk is not high; adding mechanical prophylaxis is suggested. This is not a universal treatment threshold for every vascular operation or trauma admission .

Procedure-specific prophylaxis

  • Major general surgery

    Approach and qualification
    ASH suggests pharmacological prophylaxis, using low-molecular-weight heparin or unfractionated heparin, with the decision modified by bleeding risk .

  • Laparoscopic cholecystectomy without additional major risk factors

    Approach and qualification
    ASH suggests against routine pharmacological prophylaxis. Previous VTE, thrombophilia or malignancy may change the assessment .

  • Major vascular surgery

    Approach and qualification
    The 2024 European cardiovascular-surgery guideline suggests considering initiation less than 24 hours after surgery for increased procedural risk, including open thoracoabdominal aortic surgery, abdominal aortic aneurysm repair and thoracic endovascular aortic repair, and for patients with additional VTE risk factors. This is a Grade 2C recommendation, not a mandate for every vascular procedure. ASH 2019 allowed either pharmacological prophylaxis or no pharmacological prophylaxis for its broader cardiac/major-vascular category because certainty was very low .

  • Major trauma

    Approach and qualification
    ASH suggests pharmacological prophylaxis when bleeding risk is low or moderate, but not while bleeding risk is high. Reassess as injuries and haemostasis evolve; a Caprini threshold does not replace the trauma-specific assessment .

  • Major abdominal-pelvic cancer surgery

    Approach and qualification
    Four weeks of postoperative low-molecular-weight heparin is recommended when bleeding risk is not high .

ASCO 2023 added apixaban and rivaroxaban as weakly recommended options for extended prophylaxis after cancer surgery. That recommendation does not create an authorised cancer-surgery prophylaxis indication in the European product information cited here; guideline-supported use and regulatory authorisation must be distinguished .

For acutely ill medical inpatients, Padua ≥4 identifies increased VTE risk. The IMPROVE bleeding model identifies a higher-risk group at a score ≥7, but neither score independently determines whether an individual should receive anticoagulant prophylaxis. IMPROVE was developed for bleeding after medical admission, not for deciding whether to withhold therapeutic anticoagulation for established .

Pharmacological options for eligible medical inpatients include low-molecular-weight heparin, unfractionated heparin and fondaparinux. Select the product and dose for the indication and renal function rather than applying one dose-reduction or anti-Xa-monitoring rule to the entire group. When pharmacological prophylaxis cannot be given, use suitable mechanical prophylaxis where feasible, ensure that prescribed intermittent pneumatic compression is worn, and reassess eligibility for medication .

MEDENOX (1999) tested enoxaparin 40 mg once daily for 6–14 days against placebo in acutely ill medical inpatients. VTE by day 14 occurred in 5.5% versus 14.9% of evaluable patients; the endpoint included screening-detected DVT and was not restricted to symptomatic events .

Repeat the assessment after bleeding, reoperation, or a material change in renal function or mobility .

Diagnosis

Compression duplex ultrasonography is the first-line imaging test for suspected lower-extremity deep vein thrombosis. Interpretation depends on pretest probability, the venous segments examined and examination quality .

In outpatients, a modified Wells score of 1 or less with a negative high-sensitivity D-dimer excludes deep vein thrombosis without imaging . A higher Wells category or a positive D-dimer requires compression duplex ultrasonography.

D-dimer specificity is low in inpatients and in patients with cancer, pregnancy, or advanced age; a positive result in these groups is rarely discriminating . In a post-operative or cancer inpatient with high clinical suspicion, diagnosis proceeds directly to compression duplex ultrasonography .

Further Assessment After Initial Ultrasound
Comparison A

Negative proximal compression ultrasound with persistent clinical suspicion

Trade-offs
  • A negative limited examination does not exclude every distal or evolving thrombus
Comparison B

Suspected iliac or pelvic thrombosis with an inconclusive or technically limited examination

Trade-offs
  • Routine leg compression ultrasound may not adequately assess pelvic veins

Anticoagulation

Acute proximal DVT is treated with anticoagulation unless contraindicated. Isolated distal DVT requires assessment of symptoms, extension risk and the suitability of ultrasound follow-up. A direct oral anticoagulant is generally preferred to a vitamin K antagonist in eligible non-cancer patients .

Before prescribing, review bleeding, recent procedures, platelet count, renal and hepatic function, age, weight, concomitant antiplatelet treatment and drug interactions. Apply the drug’s own dosing criteria; a restriction affecting one anticoagulant is not necessarily a contraindication to all anticoagulation.

These are adult EU/EEA treatment regimens, not atrial-fibrillation, postoperative-prophylaxis or paediatric regimens. Creatinine-clearance thresholds are expressed in mL/min; use the appropriate Cockcroft–Gault estimate when applying these dosing instructions. Extended-treatment doses are discussed in the duration section .

Decision threshold

Apixaban

Which value triggers which action?

  1. Apixaban
    Use cautiously at CrCl 15–29; not recommended below 15 or during dialysis under the cited European label. Age or low weight alone does not reduce the acute-VTE dose. Do not import the atrial-fibrillation dose-reduction criteria into DVT/PE treatment .
    10 mg twice daily for 7 days, then 5 mg twice daily. No mandatory parenteral lead-in.
  2. Rivaroxaban
    Use cautiously at CrCl 15–29; not recommended below 15. At CrCl 15–49, reduction from 20 to 15 mg once daily after the first 21 days may be considered only when bleeding risk outweighs recurrence risk. This reduced continuing regimen is based on pharmacokinetic modelling and was not clinically studied in this setting. No automatic adult age- or weight-based reduction applies .
    15 mg twice daily for 21 days, then 20 mg once daily. Take both the 15-mg and 20-mg doses with food. No mandatory parenteral lead-in.
  3. Edoxaban
    Use 30 mg once daily if any of the following applies: CrCl 15–50, body weight ≤60 kg, or concomitant ciclosporin, dronedarone, erythromycin or ketoconazole. This interaction rule does not extend automatically to every P-glycoprotein inhibitor. Not recommended below CrCl 15 or during dialysis .
    At least 5 days of parenteral anticoagulation, then 60 mg once daily.
  4. Dabigatran
    CrCl <30 is contraindicated. The European label recommends 110 mg twice daily at age ≥80 or with verapamil, and permits consideration of that dose at age 75–80, CrCl 30–50, with gastritis/oesophagitis/gastro-oesophageal reflux, or other increased bleeding risk. The 110-mg twice-daily DVT/PE regimen is pharmacokinetically supported but was not studied clinically in this setting. Weight <50 kg warrants close observation, not an invented weight-based dose .
    At least 5 days of parenteral anticoagulation, then usually 150 mg twice daily.

The pivotal trials used different bleeding endpoints. AMPLIFY demonstrated non-inferiority for recurrent symptomatic VTE or VTE-related death and less major bleeding. HOKUSAI-VTE demonstrated non-inferiority for recurrent VTE and less major-or-clinically-relevant-nonmajor bleeding. EINSTEIN-DVT reported equal rates of that bleeding composite in its two treatment groups. RE-COVER did not demonstrate a significant reduction in major bleeding .

Restrictions and circumstances requiring a different treatment plan

  • Hepatic disease

    Practical implication
    Apixaban and edoxaban are contraindicated with hepatic coagulopathy carrying clinically relevant bleeding risk, are not recommended in severe hepatic impairment, and require caution in mild/moderate impairment. Rivaroxaban is contraindicated with hepatic coagulopathy and clinically relevant bleeding risk, including cirrhosis with Child–Pugh B or C. Dabigatran is contraindicated when hepatic impairment or disease is expected to affect survival; use is not recommended with liver enzymes >2 times the upper limit of normal .

  • Mechanical heart valve

    Practical implication
    Maintain valve-directed vitamin K antagonist treatment; a DOAC is not an appropriate substitute. This is a drug-selection restriction, not a reason to withhold all anticoagulation .

  • Antiphospholipid syndrome, particularly triple positivity

    Practical implication
    DOACs are not recommended under the European label warnings; vitamin K antagonist treatment is generally preferred .

  • Severe or unstable renal dysfunction

    Practical implication
    Apply the individual drug restrictions above. Unfractionated heparin followed by a vitamin K antagonist is an option; low-molecular-weight heparin is not an unrestricted replacement because accumulation may occur .

  • Pregnancy or breastfeeding

    Practical implication
    Low-molecular-weight heparin is preferred during pregnancy and is an option during breastfeeding. Regulatory wording differs: rivaroxaban and edoxaban are contraindicated in pregnancy and breastfeeding; apixaban should preferably be avoided in pregnancy and requires a choice between breastfeeding and treatment; dabigatran should be avoided in pregnancy unless clearly necessary, and breastfeeding should be stopped during treatment .

  • Active clinically significant bleeding

    Practical implication
    Control bleeding and reassess anticoagulation promptly. For acute proximal DVT when anticoagulation cannot be given, consider a temporary/retrievable vena cava filter. Intermittent pneumatic compression does not treat the existing DVT .

  • Recent surgery or a planned invasive procedure

    Practical implication
    There is no universal postoperative waiting period. Haemostasis, the operative site and the drug’s contraindications govern timing; recent intracranial, spinal or ophthalmic procedures may meet specific label exclusions. Anticoagulation and thrombolysis require separate risk assessments .

These are selected prescribing restrictions, not a complete interaction, peri-procedural or reversal protocol.

Endovascular and surgical treatment

Most acute lower-extremity deep vein thrombosis is managed without thrombus removal. Early removal may be considered for selected acute iliofemoral thrombosis with marked swelling, disabling pain or substantial limitation of walking, after assessment of symptom duration, functional status and patient preferences. Elective catheter-directed or pharmacomechanical thrombolysis requires low bleeding risk. Thrombus removal is additional to indicated anticoagulation when it can be given, rather than a substitute for it. Femoral-popliteal or calf thrombosis alone is not a routine indication .

Catheter-directed thrombolysis, pharmacomechanical treatment and selected mechanical are distinct options. Evidence obtained with thrombolytic regimens cannot automatically establish the comparative benefits of lytic-free thrombectomy. Phlegmasia with threatened limb viability requires urgent vascular assessment and a limb-salvage strategy; it is not managed within the elective symptom-selection framework .

After thrombus removal, a significant residual iliac outflow lesion may prompt consideration of stenting. May–Thurner anatomy alone does not mandate a stent. Intravascular ultrasound helps assess the lesion and plan stent dimensions and landing zones, but much of its comparative evidence concerns chronic obstruction or nonthrombotic lesions rather than prevention of re-thrombosis after acute DVT. Anticoagulation remains necessary according to the underlying VTE indication .

Randomized evidence differs by population, technique and endpoint. ATTRACT (2017) found no overall reduction in PTS with pharmacomechanical treatment and more major bleeding. Its iliofemoral analysis (2019) found benefits in early symptoms and PTS severity, not the occurrence of any PTS. CaVenT reported less PTS after catheter-directed thrombolysis at two and five years, whereas CAVA (2020) did not demonstrate a significant one-year preventive benefit. These findings support selective discussion rather than a universal intervention-first approach .

Non-limb-threatening DVT with tolerable symptoms
  • Management approach
    Anticoagulation when indicated, without routine thrombus removal
    Important qualification
    Clot presence alone does not establish procedural benefit

  • Acute iliofemoral DVT with disabling symptoms

    Management approach
    Consider early thrombus removal in an appropriately selected patient
    Important qualification
    Elective lytic procedures require low bleeding risk. Discuss uncertain long-term benefit and anticoagulation without intervention

  • Phlegmasia with threatened limb viability

    Management approach
    Urgent endovascular or surgical limb-salvage treatment
    Important qualification
    Procedure selection depends on limb status, anatomy, bleeding risk and available expertise

A retrievable vena cava filter may be considered for acute proximal DVT when anticoagulation is contraindicated. It is not routinely added to effective anticoagulation and should be removed when anticoagulation can safely resume. Detailed filter management is covered in the pulmonary embolism and vena cava filter chapter .

Cancer-associated venous thromboembolism

Cancer-associated VTE can be treated with low-molecular-weight heparin or, in suitable patients, apixaban, edoxaban or rivaroxaban. Cancer-specific guidance should be used rather than extrapolating the non-cancer ASH treatment guideline or treating all DOACs as interchangeable .

Assess the tumour and any active mucosal lesion, not only the organ label. An unresected intraluminal gastrointestinal or genitourinary tumour warrants particular caution and may favour low-molecular-weight heparin. ITAC’s recommendation for an oral factor Xa inhibitor applies when creatinine clearance is ≥30 mL/min, gastrointestinal/genitourinary bleeding risk is not high and important drug interactions or impaired gastrointestinal absorption are absent. Review systemic therapy, platelet count, renal and hepatic function, oral intake and planned procedures; low-molecular-weight heparin also requires patient-specific prescribing .

Cancer-associated VTE: what the pivotal trials established

  • CLOT, 2003: dalteparin versus a coumarin-based regimen; six months

    Main result and qualification
    Estimated recurrent VTE was 9% versus 17% (HR 0.48). Major bleeding did not differ significantly. This supports dalteparin over the tested coumarin strategy, not superiority of every low-molecular-weight heparin regimen over every oral anticoagulant .

  • CATCH, 2015: tinzaparin versus warfarin; six months

    Main result and qualification
    Cumulative recurrent VTE was 7.2% versus 10.5% (HR 0.65, 95% CI 0.41–1.03; P=0.07). The primary result did not establish superiority. Clinically relevant nonmajor bleeding was lower with tinzaparin; major bleeding was not significantly different .

  • HOKUSAI VTE Cancer, 2018: edoxaban after heparin versus dalteparin; outcome assessment through 12 months

    Main result and qualification
    Non-inferiority concerned the composite of recurrent VTE or major bleeding: 12.8% versus 13.5%. Recurrent VTE was 7.9% versus 11.3%, while major bleeding was 6.9% versus 4.0%. Do not describe this as a recurrence-only non-inferiority finding .

  • SELECT-D, 2018: rivaroxaban versus dalteparin; six months

    Main result and qualification
    This was a pilot trial, not a formal recurrence non-inferiority trial. Cumulative recurrent VTE was 4% versus 11%; major bleeding was 6% versus 4% with an imprecise HR of 1.83 (95% CI 0.68–4.96). Clinically relevant nonmajor bleeding was 13% versus 4%. Oesophageal/gastro-oesophageal cancers were excluded from further enrolment after an interim safety concern .

  • Caravaggio, 2020: apixaban versus dalteparin; six months

    Main result and qualification
    Recurrent VTE was 5.6% versus 7.9%, meeting non-inferiority; major bleeding was 3.8% versus 4.0%. The overall result supports apixaban as an option in appropriately selected patients, but does not establish safety for every unresected luminal lesion .

These trials are not head-to-head comparisons of the oral agents. Differences in populations, follow-up and bleeding endpoints prevent a simple drug ranking. In particular, an overall trial result must not override a patient’s active bleeding lesion or a product-specific contraindication. Duration and dosing beyond six months are addressed below .

Duration, compression, and secondary prevention

For proximal DVT provoked by a major transient risk factor, three months of anticoagulation is generally sufficient. Unprovoked proximal DVT requires at least three months, with extended treatment considered according to recurrence and bleeding risk .

Cancer-associated VTE generally requires at least six months of treatment. Continuing thereafter depends on cancer activity and treatment, recurrence risk, bleeding, tolerability, prognosis and patient preferences; active cancer is not an instruction to continue unchanged treatment regardless of these factors .

API-CAT (2025) studied 1,766 patients with active cancer and previous proximal DVT or PE who had already completed at least six months of anticoagulation. Over a further 12 months, apixaban 2.5 mg twice daily was non-inferior to 5 mg twice daily for recurrent VTE (2.1% versus 2.8%) and reduced clinically relevant bleeding (12.1% versus 15.6%). This supports reduced-dose apixaban for suitable patients in the extended phase—not reduced-dose initial treatment or a class-wide reduction for other DOACs .

After at least six months of treatment, European authorised extended-prevention regimens include apixaban 2.5 mg twice daily and rivaroxaban 10 mg once daily; rivaroxaban 20 mg once daily remains an option when recurrence risk is high. These are drug-specific regimens, not permission to reduce any DOAC . In EINSTEIN CHOICE (2017), patients in equipoise about continuing anticoagulation after 6–12 months were assigned rivaroxaban 20 mg, rivaroxaban 10 mg or aspirin. Recurrent VTE occurred in 1.5%, 1.2% and 4.4%, respectively; major bleeding occurred in 0.5%, 0.4% and 0.3%. There was no statistically significant major-bleeding increase, but the trial did not establish equivalence of bleeding risk or equivalence between the two rivaroxaban doses . The DASH and HERDOO2 scores estimate recurrence risk after a first unprovoked event and structure the decision to stop or extend . Reassess recurrence and bleeding risk during extended treatment and when procedures, organ function or interacting treatment change; the medical-admission IMPROVE model is not a general extended-anticoagulation decision rule .

Elastic compression may be used for bothersome swelling after acute DVT, with continued use guided by suitability, symptoms and tolerance. Symptom treatment is distinct from prevention of post-thrombotic syndrome. For acute proximal DVT, ESVS 2021 recommends early compression, within 24 hours, using 30–40 mmHg hosiery or multilayer bandaging for symptoms; it also recommends considering below-knee stockings for PTS prevention. ASH 2020 suggests against routine stockings for prevention. SOX (2014) did not demonstrate a preventive benefit. Preventive benefit remains uncertain, and pain relief is not assured in every patient .

Intermittent pneumatic compression is distinct from graduated hosiery and does not replace anticoagulation for acute DVT. Its use in selected patients with established PTS is discussed in the chapter on post-thrombotic syndrome and iliocaval obstruction .

Areas of controversy

The benefits of early thrombus removal remain dependent on patient selection and the outcome assessed; symptom improvement, reduced PTS severity and prevention of any PTS are not interchangeable endpoints . Optimal duration after a first unprovoked event is unsettled, with risk-prediction tools informing rather than settling the stop-or-extend decision . Evidence supporting selected oral factor Xa inhibitors in cancer-associated VTE does not establish equal suitability across tumour sites or active mucosal lesions; bleeding risk, interactions and absorption remain decisive .

Further reading

  • Epidemiology of venous thromboembolism. (2015). VTE epidemiology background; older estimates need population and date context.
  • Basics of diagnosis and treatment of venous thromboembolism. (2025). Current diagnostic and treatment framework for DVT and PE; not a substitute for drug labeling.

References

  1. 1.
    Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. 2021.
    PubMed-indexed articleClinical practice guideline2021

    Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. 2021. doi:10.1016/j.ejvs.2020.09.023.

    PubMedDOI
  2. 2.
    American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. 2018.
    PubMed-indexed articleClinical practice guideline2018

    American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. 2018. doi:10.1182/bloodadvances.2018024828.

    PubMedDOI
  3. 3.
    Risk Factors for Venous Thromboembolism. 2003.
    PubMed-indexed articleReview2003

    Risk Factors for Venous Thromboembolism. 2003. doi:10.1161/01.cir.0000078469.07362.e6.

    PubMedDOI
  4. 4.
    Epidemiology of venous thromboembolism. 2015.
    PubMed-indexed articleReview2015

    Epidemiology of venous thromboembolism. 2015. doi:10.1038/nrcardio.2015.83.

    PubMedDOI
  5. 5.
    2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. 2024.
    PubMed-indexed article2024

    2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. 2024. doi:10.1161/cir.0000000000001209.

    PubMedDOI
  6. 6.
    The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.
    PubMed-indexed article2006

    Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722-7. doi:10.1111/j.1525-1497.2006.00458.x. PMID:16808773.

    PubMedDOI
  7. 7.
    Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.
    PubMed-indexed article2004

    Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25. doi:10.1016/j.amjmed.2004.01.018. PMID:15210384.

    PubMedDOI
  8. 8.
    Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. 2008.
    PubMed-indexed articleRegistry / cohort2008

    Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. 2008. doi:10.1016/s0140-6736(08)60202-0.

    PubMedDOI
  9. 9.
    American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. 2019.
    PubMed-indexed articleClinical practice guideline2019

    American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. 2019. doi:10.1182/bloodadvances.2019000975.

    PubMedDOI
  10. 10.
    Thrombosis risk assessment as a guide to quality patient care.
    PubMed-indexed article2005

    Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2-3):70-8. doi:10.1016/j.disamonth.2005.02.003. PMID:15900257.

    PubMedDOI
  11. 11.
    American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.
    PubMed-indexed articleClinical practice guideline2018

    Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225. doi:10.1182/bloodadvances.2018022954. PMID:30482763.

    PubMedDOI
  12. 12.
    Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.
    PubMed-indexed articleRandomized controlled trial2011

    Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69-79. doi:10.1378/chest.09-3081. PMID:20453069.

    PubMedDOI
  13. 13.
    A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. 2010.
    PubMed-indexed article2010

    A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. 2010. doi:10.1111/j.1538-7836.2010.04044.x.

    PubMedDOI
  14. 14.
    A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. 1999.
    PubMed-indexed articleRandomized controlled trial1999

    A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. 1999. doi:10.1056/nejm199909093411103.

    PubMedDOI
  15. 15.
    Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. 2003.
    PubMed-indexed article2003

    Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. 2003. doi:10.1056/nejmoa023153.

    PubMedDOI
  16. 16.
    American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. 2020.
    PubMed-indexed articleClinical practice guideline2020

    American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. 2020. doi:10.1182/bloodadvances.2020001830.

    PubMedDOI
  17. 17.
    Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
    PubMed-indexed articleClinical practice guideline2021

    Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055. PMID:34352278.

    PubMedDOI
  18. 18.
    Oral Apixaban for the Treatment of Acute Venous Thromboembolism. 2013.
    PubMed-indexed articleRandomized controlled trial2013

    Oral Apixaban for the Treatment of Acute Venous Thromboembolism. 2013. doi:10.1056/nejmoa1302507.

    PubMedDOI
  19. 19.
    Oral Rivaroxaban for Symptomatic Venous Thromboembolism. 2010.
    PubMed-indexed articleRandomized controlled trial2010

    Oral Rivaroxaban for Symptomatic Venous Thromboembolism. 2010. doi:10.1056/nejmoa1007903.

    PubMedDOI
  20. 20.
    Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. 2013.
    PubMed-indexed articleRandomized controlled trial2013

    Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. 2013. doi:10.1056/nejmoa1306638.

    PubMedDOI
  21. 21.
    Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. 2009.
    PubMed-indexed articleRandomized controlled trial2009

    Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. 2009. doi:10.1056/nejmoa0906598.

    PubMedDOI
  22. 22.
    Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.
    PubMed-indexed article2019

    Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, et al. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thromb Haemost. 2019;119(2):319-327. doi:10.1055/s-0038-1676611. PMID:30593086.

    PubMedDOI
  23. 23.
    Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. 2017.
    PubMed-indexed articleRandomized controlled trial2017

    Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. 2017. doi:10.1056/nejmoa1615066.

    PubMedDOI
  24. 24.
    Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.
    PubMed-indexed articleRandomized controlled trial2012

    Enden T, Haig Y, Kløw NE, Slagsvold CE, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379(9810):31-8. doi:10.1016/S0140-6736(11)61753-4. PMID:22172244.

    PubMedDOI
  25. 25.
    Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial.
    PubMed-indexed articleRandomized controlled trial2016

    Haig Y, Enden T, Grøtta O, Kløw NE, Slagsvold CE, Ghanima W, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016;3(2):e64-71. doi:10.1016/S2352-3026(15)00248-3. PMID:26853645.

    PubMedDOI
  26. 26.
    Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. 2003.
    PubMed-indexed articleRandomized controlled trial2003

    Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. 2003. doi:10.1056/nejmoa025313.

    PubMedDOI
  27. 27.
    Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer. 2015.
    PubMed-indexed articleRandomized controlled trial2015

    Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer. 2015. doi:10.1001/jama.2015.9243.

    PubMedDOI
  28. 28.
    Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. 2018.
    PubMed-indexed articleRandomized controlled trial2018

    Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. 2018. doi:10.1056/nejmoa1711948.

    PubMedDOI
  29. 29.
    Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). 2018.
    PubMed-indexed articleRandomized controlled trial2018

    Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). 2018. doi:10.1200/jco.2018.78.8034.

    PubMedDOI
  30. 30.
    Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. 2020.
    PubMed-indexed articleRandomized controlled trial2020

    Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. 2020. doi:10.1056/nejmoa1915103.

    PubMedDOI
  31. 31.
    Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. 2017.
    PubMed-indexed articleRandomized controlled trial2017

    Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. 2017. doi:10.1056/nejmoa1700518.

    PubMedDOI
  32. 32.
    Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH).
    PubMed-indexed articleMeta-analysis / systematic review2012

    Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-25. doi:10.1111/j.1538-7836.2012.04735.x. PMID:22489957.

    PubMedDOI
  33. 33.
    Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.
    PubMed-indexed articleRandomized controlled trial2008

    Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417-26. doi:10.1503/cmaj.080493. PMID:18725614.

    PubMedDOI
  34. 34.
    Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. 2014.
    PubMed-indexed articleRandomized controlled trial2014

    Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. 2014. doi:10.1016/s0140-6736(13)61902-9.

    PubMedDOI
  35. 35.
    Compression therapy for prevention of post-thrombotic syndrome.
    PubMed-indexed articleMeta-analysis / systematic review2017

    Appelen D, van Loo E, Prins MH, Neumann MH, Kolbach DN. Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev. 2017;9(9):CD004174. doi:10.1002/14651858.CD004174.pub3. PMID:28950030.

    PubMedDOI
  36. 36.
    The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.
    PubMed-indexed articleClinical practice guideline2014

    Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636-61. doi:10.1161/CIR.0000000000000130. PMID:25246013.

    PubMedDOI
  37. 37.
    Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    No stable evidence link
    researchgate.net2012
    Source
  38. 38.
    European guidelines on perioperative venous thromboembolism prophylaxis: Cardiovascular surgery.
    No stable evidence link
    academic.oup.com2024
    Source
  39. 39.
    2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
    No stable evidence link
    sciencedirect.com2022
    Source
  40. 40.
    Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.
    PubMed-indexed article2023
    PubMed
  41. 41.
    Eliquis — EPAR Product Information.
    EMA
    Source
  42. 42.
    Xarelto — EPAR Product Information.
    EMA
    Source
  43. 43.
    Lixiana — EPAR Product Information.
    EMA
    Source
  44. 44.
    Pradaxa — EPAR Product Information.
    EMA
    Source
  45. 45.
    2025 ESC/EACTS Guidelines for the management of valvular heart disease.
    PubMed-indexed article2025
    PubMed
  46. 46.
    Society of Interventional Radiology Position Statement on the Endovascular Management of Acute Iliofemoral Deep Vein Thrombosis.
    No stable evidence link
    profiles.wustl.edu2023
    Source
  47. 47.
    Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction.
    No stable evidence link
    profiles.wustl.edu2017
    Source
  48. 48.
    Consensus Statement on the Management of Nonthrombotic Iliac Vein Lesions From the VIVA Foundation, the American Venous Forum, and the American Vein and Lymphatic Society.
    No stable evidence link
    viva-foundation.org2024
    Source
  49. 49.
    Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis: Analysis From a Stratified Multicenter Randomized Trial.
    PubMed-indexed article2019
    PubMed
  50. 50.
    Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial.
    PubMed-indexed article2020
    PubMed
  51. 51.
    Treatment of Venous Thromboembolism (VTE) in Patients with Cancer.
    No stable evidence link
    hematology.org2023
    Source
  52. 52.
    Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.
    PubMed-indexed article2025
    PubMed
  53. 53.
    Guidance for the prevention and treatment of the post-thrombotic syndrome.
    PubMed Central2016
    Source
  54. 54.
    Basics of diagnosis and treatment of venous thromboembolism. 2025.
    PubMed-indexed article2025

    Basics of diagnosis and treatment of venous thromboembolism. 2025. doi:10.1016/j.jtha.2025.01.009.

    PubMedDOI

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions
Updates and feedback

You are reading the published chapter.

What has changed

Loading the change history…

Report a problem